Beam Therapeutics Inc. (BEAM) – Press Releases
-
Beam Therapeutics Announces Clearance of Clinical Trial Authorisation Application for BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
-
2024 Entrepreneurship Summit Presented by the Harvard Undergraduate Venture Capital Group: Agenda and Speakers
-
Beam Therapeutics to Participate in Upcoming March 2024 Investor Conferences
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Reiterates Anticipated Milestones
-
Beam Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
-
Beam Therapeutics Highlights Progress Across Base Editing Portfolio and Outlines 2024 Anticipated Milestones
-
Beam Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
-
Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors
-
Beam Therapeutics Reports Pipeline and Business Updates and Third Quarter 2023 Financial Results
-
Beam Therapeutics to Participate in 2023 Jefferies London Healthcare Conference
-
Beam Announces Agreement for Lilly to Acquire Beam’s Opt-In Rights to Verve Therapeutics’ Base Editing Programs for Cardiovascular Disease
-
Beam Therapeutics Presents Preclinical Data Highlighting Utility and Durability of BEAM-301 to Correct a Glycogen Storage Disease Type I Deficiency Disease-Causing Mutation at ESGCT
-
Beam Therapeutics Announces Portfolio Prioritization and Strategic Restructuring Focused on Potential Near-term Value Drivers and Long-term Growth of Precision Genetic Medicines Pipeline
-
Beam Therapeutics Presents Preclinical Data Highlighting Utility of BEAM-302 to Correct an Alpha-1 Antitrypsin (AAT) Deficiency Disease-Causing Mutation
-
Beam Therapeutics Announces First Patient Dosed in Phase 1/2 Trial of BEAM-201 in Relapsed, Refractory T-ALL/T-LL
-
Beam Therapeutics to Participate in Upcoming September Investor Conferences
-
Beam Therapeutics Reports Pipeline Updates and Second Quarter 2023 Financial Results
-
Beam Therapeutics to Participate in Upcoming May Investor Conferences
-
Beam Therapeutics to Participate in RBC Capital Markets 2023 Global Healthcare Conference
-
Beam Therapeutics Reports Pipeline Updates and First Quarter 2023 Financial Results
-
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
-
Beam Therapeutics to Participate in the Guggenheim 2023 Genomic Medicines and Rare Disease Day
-
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
-
Beam Therapeutics Appoints Gopi Shanker, Ph.D., as Chief Scientific Officer
-
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
-
Beam Therapeutics to Participate in the Barclays 2023 Global Healthcare Conference
-
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
-
Beam Therapeutics to Participate in the 43rd Annual Cowen Healthcare Conference
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
-
Beam Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Reiterates Anticipated Milestones
-
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
-
Beam Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference
-
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
-
Beam Therapeutics Reports Progress Across Base Editing Portfolio and Outlines Key Anticipated Milestones
-
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Beam Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead o
-
Beam Therapeutics Presents First In Vivo Proof of Concept Preclinical Data on Multiplex Base Edited ESCAPE Platform for Non-Genotoxic Conditioning Regimen for Patients with Sickle Cell Disease Ahead o
-
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
-
Beam Therapeutics Named to Boston Globe’s Top Places to Work List for 2022
-
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
-
Beam Therapeutics Announces FDA Has Lifted the Clinical Hold on the Investigational New Drug Application for BEAM-201
-
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
-
Beam Therapeutics to Participate in the BofA Securities 2022 Virtual Biotech SMID Cap Conference
-
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
-
Beam Therapeutics Enrolls First Patient in BEACON Clinical Trial of BEAM-101 Base Editing Therapy Candidate for the Treatment of Sickle Cell Disease
-
Beam Therapeutics to Participate in Upcoming Investor Conferences
-
Beam Therapeutics to Participate in Upcoming Investor Conferences
-
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
-
Beam Therapeutics Announces Portfolio Progress and Reports Third Quarter 2022 Financial Results
Back to BEAM Stock Lookup
